The Ministry of Industry and Trade of the Russian Federation is developing a support mechanism for projects related to the development of original medicinal products. The draft resolution is posted on the portal of draft legal acts.
The initiative provides for compensation to Russian companies for the costs of conducting the final phase of clinical trials preceding the receipt of a certificate of approval for the original drug, or the expansion of indications for the use of drugs.
Project selection is planned to begin in 2026, with payments starting from 2027. Support for one project will be 250 million rubles. Before the selection process begins, the Ministry of Health will identify in-demand biomedicines and therapeutic areas.
“The implementation of this draft decree will contribute to transitioning the domestic pharmaceutical industry to an innovative development model, expand the range of developed original drugs, stimulate domestic research and development, and increase the volume of investments by Russian pharmaceutical companies in the development of new products,” the message states.
